BiotechJanuary 22, 2016
Money from Genes: CRISPR Goes Commercial
The new DNA-changing tech has attracted millions of dollars from AstraZeneca, DuPont and other big companies
Stories by Katrina Megget
Money from Genes: CRISPR Goes Commercial
The new DNA-changing tech has attracted millions of dollars from AstraZeneca, DuPont and other big companies